NTRX 07
Alternative Names: MDA-7; NTRX-07Latest Information Update: 16 Apr 2026
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Cleveland Clinic; NeuroTherapia; University of Texas M. D. Anderson Cancer Center
- Class Analgesics; Antidementias; Benzofurans; Benzyl compounds; Heterocyclic compounds; Neuroprotectants; Piperidines; Small molecules
- Mechanism of Action Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
- No development reported Neuropathic pain
Most Recent Events
- 07 Apr 2026 Preliminary pharmacodynamics and adverse events data from a phase-IIa trial in Alzheimer's disease released by NeuroTherapia
- 07 Apr 2026 NeuroTherapia completes a phase-IIa trial in Alzheimer's disease (In the elderly) in Hungary, Poland, and the Czech Republic (PO), (NCT07058688)
- 07 Apr 2026 NeuroTherapia plans a phase-II trial for Alzheimer's disease (PO),